Abstract. Cisplatin (CDDP) is a DNA damaging agent and is widely used for treating cancer. While the role of p53 in CDDP-induced cell death has been stressed, evidence exists that CDDP can also kill p53-mutated cells. To investigate the latter mechanism, we performed a comparative study using three different human cell types, SNU-16 (a stomach cancer cell-line), U937 (a leukemic cell-line) and 293T (a kidney fibroblast cell-line), which are defective in terms of p53 activation. A focus was placed on Bcl-2 family proteins, reactive oxygen species (ROS), and mitogen-activated protein kinases. Our results suggest that the ability of CDDP to kill these cells can be mediated by JNK, p38 MAPK and ROS, but not by ERK. It was also found that CDDP can increase the ratio of proapoptotic/pro-survival Bcl-2 members. While the importance of these components was found to depend on cell type, JNK was commonly involved in the deaths of all cell types examined. Therefore, the JNK pathway appears to be an ideal target for the modulation of the lethal action of CDDP in multiple types of p53-mutated cells.
Introduction
Cisplatin (cis-diammine-dichloro-platinum, CDDP) is a DNA damaging agent and is widely used for anticancer treatment. The major limitation of successful chemotherapy is the development of tumor cell resistance to this drug (1) . To overcome this problem, it is essential that the cellular components involved in CDDP-induced cell death be identified. In particular, information regarding components that act in a broad spectrum of cell types would be useful for the development of more general therapeutic strategies.
P53 is a transcription factor that plays a key role in DNA damage check-point control (2, 3) . In response to DNA damage caused by anticancer drugs or ionizing radiation, p53 is stabilized and activated, and then coordinates DNA repair with cell cycle progression and apoptosis. The mechanism underlying the apoptotic action of p53 has been extensively characterized. Consequently, it has been well established that p53 can induce the expression of various types of pro-apoptotic proteins, such as Bax (4), Noxa (5) and Puma (6, 7) . It has also been reported that p53 can cause the down-regulation of the pro-survival protein, Bcl-2 (8) .
P53 also responds to CDDP and plays a crucial role in CDDP-induced cell death (9) . This finding led some investigators to hypothesize that a loss of p53 function may contribute to the development of tumor cell resistance to CDDP. In fact, it was reported that p53 is mutated in >50% of tumor cells (10) (11) (12) . However, many of these tumors, despite the loss of p53 activation, remain responsive to CDDP. It has also been consistently demonstrated that disruption of p53 function does not make tumor cells resistant to CDDP (13, 14) . These observations suggest that CDDP can induce cell death in an alternative p53-independent manner. However, to date, cellular components involved in the p53-independent action of CDDP have not been systemically analyzed.
It has been reported that CDDP can influence the levels and activities of various types of cell death modulators, such as reactive oxygen species (ROS), mitogen-activated protein kinases (MAPKs) and Bcl-2 family proteins. For example, treating Jurkat leukemia cells with CDDP increased cellular ROS levels, and the prevention of this increase using antioxidants protected the cells against CDDP (15) . Similar observations have been reported for testicular germ cell tumors (16) , thus suggesting that ROS may act as mediators of CDDPinduced cell death. Major MAPK subfamily members include extracellular signal-regulated kinase (ERK), p38 kinase and c-Jun N-terminal kinase (JNK). It was reported that CDDP can kill HeLa cervical carcinoma cells by activating p38 MAPK and JNK (17) . In addition, JNK was proposed to play a role in CDDP-induced cell death in A2780 ovarian cancer cells (18) . The Bcl-2 family proteins include pro-apoptotic members such as Bax and Bak, in addition to pro-survival members such as Bcl-2 and Bcl-X L (19) . It was reported that treating OSC-4 oral carcinoma cells with CDDP caused increased levels of Bax and Bak and decreased Bcl-2 and Bcl-X L (20) . These alterations may be critical for the lethal action of CDDP, given the view that cellular viability is determined by the balance between pro-apoptotic and pro-survival Bcl-2 family members (21) . Despite the proposed roles of ROS, MAPKs and Bcl-2 family members in CDDP-induced cell death, the relationships between their actions and p53 function have not been clearly established.
In this study, we investigated whether ROS, MAPKs and Bcl-2 family proteins are involved in CDDP-induced cell death in the absence of p53 activation. In addition, to determine whether their actions are confined to a specific cell type, we performed a comparative study using three different human cell types, SNU-16 (a stomach cancer cell-line), U937 (leukemic cells) and 293T (kidney fibroblasts), which commonly show defective p53 activation. Our results suggest that CDDP can kill these cells via multiple cell type dependent mechanisms. Interestingly, unlike ERK, p38 MAPK, ROS and Bcl-2 family members, JNK was found to be commonly involved in the CDDP-induced death of all three cell types. Therefore, it appears that the JNK pathway could be a primary target for modulating the lethal action of CDDP in the absence of p53 activation.
Materials and methods
Antibodies. The antibodies raised against Bax, Bcl-2, ERK and p38 MAPK were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies against Bak and JNK were obtained from PharMingen/Transduction Laboratories (San Diego, CA). Antibodies specific to ·-tubulin and Bcl-X L were supplied by Calbiochem (La Jolla, CA). Anti-p53 was purchased from Dako (Glostrup, Denmark).
Cell culture and treatments. Cell culture medium and its supplements were supplied by BioWhittaker (Walkersville, MD). SNU-16, U937 and 293T cells were cultured in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum and gentamicin (50 μg/ml). Human umbilical vein endothelial cells (HUVECs) were purchased from BioWhittaker, and maintained in EGM-2 medium supplemented with 20% heat-inactivated fetal bovine serum and endothelial cell growth factors (30 μg/ml). To treat the cells, U937 and SNU-16 cells were resuspended in a concentration of 1.5x10 5 cells/ml. HUVEC and 293T cells were replated in either 24-well plates (10 5 cells/well) or 100-mm culture dishes (2x10 6 cells/dish). The cells were allowed to adhere overnight and then given the indicated treatments. Where specified, catalase and rotenone, inhibitors for MAPKs, were added at the indicated concentrations.
Analysis of cellular viability. The treated and untreated control cells were stained with propidium iodide (5 μg/ml) followed by flow cytometry analysis to monitor their staining intensity and size. The cells displaying both a normal size and a low permeability to propidium iodide were understood to be viable, as previously defined (22) . All other populations were understood to be dead.
Analysis of cellular ROS levels.
The cells were exposed to 50 μM 2',7'-dichlorofluorescein diacetate (DCFH-DA; Molecular Probes, Eugene, OR) for 5 min, and cell-associated levels of DCF fluorescence were analyzed by flow cytometry (23) . Alternatively, fluorescence images were acquired and analyzed using a Leica TCS SP2 laser scanning confocal microscope (Leica Microsystems, Heidelberg).
Western blot analysis. Cells were lysed in Tris-HCl (40 mM, pH 8), 120 mM NaCl, 0.5% Nonidet P-40, and protease inhibitors (2 μg/ml aprotinin, 2 μg/ml leupeptin and 100 μg/ ml PMSF). Equal amounts of the proteins were separated by SDS-PAGE and then electrotransferred to Immobilon membranes (Millipore, Bedford, MA), which were subsequently blotted using the indicated antibodies and visualized by chemiluminescence (ECL; Amersham Pharmacia, Uppsala, Sweden).
In vitro kinase assay. Cells were lysed in a buffer defined previously (24) . The lysate proteins (400 μg) were immunoprecipitated using antibodies against ERK, p38 MAPK or JNK and were resolved in 20 μl of a kinase buffer containing 20 mM Hepes (pH 7.4), 10 mM MgCl 2 , 20 mM ß-glycerophosphate, 10 mM NaF, 1 mM DTT, 0.5 mM sodium orthovanadate, 50 μM ATP and 10 μCi Á-[
32 P]ATP. The kinase reactions were initiated by adding 2 μg of recombinant c-Jun protein (New England Biolabs, Beverly, MA) for JNK, and PHAS-1 (Stratagene, La Jolla, CA) for ERK and p38 MAPK. After 30-min incubation, the reactions were quenched by adding a boiled sample buffer, and the proteins were subsequently separated using 12% SDS-PAGE. A PhosphoImager using Tina 2.0 software was used to analyze the results.
Results and discussion

Cell death induced by CDDP in the absence of p53 activation.
To identify the cellular components involved in CDDP-induced cell death in the absence of p53 activation, we used three different cell types, i.e. U937, SNU-16 and 293T cells. U937 cells have a p53 null mutation and, thus, do not express p53, which we confirmed by Western blotting (data not shown). SNU-16 cells also have a p53 mutation and p53 is inactivated in 293T cells by the action of SV40 T antigen. Therefore, we expected that, in SNU-16 and 293T cells, p53 would not be stabilized or activated in response to DNA damage. To confirm this, these two cell types were treated with DNA damaging agents, i.e. Á-rays and CDDP. As expected, these treatments failed to increase p53 levels, as determined by Western blotting, for up to 8 h after treatment (Fig. 1A) . In contrast, the same treatments efficiently elevated p53 levels in HUVECs (primary cultured normal endothelial cells), which was evident at only 30 min and 1 h after treating them with Á-rays or CDDP, respectively. Therefore, it was evident that p53 is either not expressed or inactivated in U937, SNU-16 and in 293T cells.
Despite their lack of a p53 response, U937, SNU-16 and 293T cells succumbed to CDDP treatment (Fig. 1B) . In the case of SNU-16 and U937 cells, 70-80% were killed by 50 μM CDDP. Further elevation of the CDDP concentration to 250 μM resulted in a marginal increase in cell death. In contrast, 50 μM CDDP killed only ~40% of 293T cells and 250 μM CDDP was required to kill 70-80%. Considering these results, we used 50 μM CDDP for SNU-16 and U937 cells and 250 μM for 293T in subsequent experiments.
Roles of Bcl-2 family members.
It has been reported that CDDP can increase Bax/Bcl-2 ratios (20) . Thus, to investigate whether this occurs in 293T, SNU-16 and U937 cells, we exposed them to lethal concentrations of CDDP. After various incubation times, the cellular levels of pro-apoptotic (Bax and Bak) and pro-survival (Bcl-2 and Bcl-X L ) members were compared by Western blotting. In 293T and SNU-16 cells, CDDP did not significantly up-regulate Bax and Bak nor down-regulate Bcl-2 and Bcl-X L (Fig. 2) and, in U937 cells, CDDP did not significantly influence Bcl-X L levels. However, CDDP did elevate Bax and Bak levels in U937 cells at 7 and 15 h, respectively, after its treatment. Moreover, CDDP reduced Bcl-2 levels in U937 cells, which was optimally observed at 15 h. CDDP consistently increased levels of Bcl-2 ubiquitination, as analyzed by Western blotting at 15 h (data not shown), which suggests that CDDP reduces Bcl-2 levels in U937 cells by promoting its degradation. These results suggest that CDDP increases the ratio of pro-apoptotic to pro-survival Bcl-2 family proteins in U937 cells, but not in the other cell types tested. Although it has been reported that p53 can up-regulate and down-regulate levels of Bax and Bcl-2 respectively (4,8), our data suggest that CDDP can do this in a p53-independent manner.
Role of ROS.
To investigate whether lethal concentrations of CDDP increase cellular ROS levels, CDDP-treated and untreated control cells were stained with DCF, and cellassociated levels of DCF fluorescence were compared by flow cytometry. CDDP treatment elevated DCF fluorescence in 293T cells (Fig. 3A) , and this effect peaked after 5 h. Similar results were obtained when DCF fluorescence was analyzed by confocal microscopy (Fig. 3B ). These observations suggest that CDDP increases ROS levels in 293T cells. The increase in DCF fluorescence was prevented when 293T cells were co-treated with rotenone (0.1 μM), an inhibitor of the mitochondrial respiratory chain (mean values of DCF fluorescence by flow cytometry were as follows; untreated, 4.45; rotenone-treated, 3.27; CDDP-treated, 12.26; CDDP and rotenone-treated, 5.21). Therefore, CDDP appears to promote mitochondrial ROS production in 293T cells, as has been proposed in Jurkat T cells (15) . In contrast, CDDP failed to increase DCF fluorescence in U937 and in SNU-16 cells. This was confirmed by flow cytometry (Fig. 3A) or confocal microscopy (data not shown) assays, which were followed from 5 min to 24 h after treatment. Consistent with these results, the CDDP-induced death of 293T cells, but not of SNU-16 or U937, was attenuated when cells were co-treated with rotenone or catalase, a H 2 O 2 -degrading enzyme (Fig. 3C) . Therefore, ROS appear to mediate the lethal action of CDDP in 293T cells, but not in U937 and SNU-16 cells.
Roles of MAPKs.
The role of ERK in CDDP-induced cell death remains controversial. For example, though it was proposed that ERK mediates the lethal action of CDDP in HeLa cells (25) , others reported that CDDP failed to activate ERK in these cells (17) . To determine the role of ERK in the present systems, its activity was analyzed by using in vitro kinase assays at various times after CDDP treatment. It was found that CDDP activated ERK in 293T and U937 cells but not in SNU-16 cells (Fig. 4A) . However, PD 98059, an ERK inhibitor, failed to rescue any of these cell types from CDDP-induced cell death (Fig. 4B) . Therefore, it appears that CDDP-induced cell death is not always accompanied by ERK activation, and that ERK, though activated, does not support the lethal action of CDDP.
In contrast to ERK, CDDP activated p38 MAPK and JNK in all three cell lines (Fig. 4A) . However, SB 203580, an inhibitor of p38 MAPK, suppressed the lethal action of CDDP only in U937 cells and not in 293T and SNU-16 ( Fig. 4B) , suggesting that p38 MAPK mediates the CDDP-induced death of U937 cells, but not that of the other two cell-lines. Therefore, the role of p38 MAPK in CDDP-induced death appears to depend on cell type. In contrast, the lethality by CDDP was reduced in all three cell types when they were co-treated with SP 600125, an inhibitor for JNK, suggesting that JNK acts as a common mediator of CDDP-induced cell death.
This study shows that CDDP can kill p53-deficient/mutated cells via multiple mechanisms, which are summarized in Table I . Our data suggests that the lethal action of CDDP can be mediated by JNK, p38 MAPK or ROS, and that CDDPinduced cell death can be accompanied by an increase in proapoptotic and a decrease in pro-survival members of the Bcl-2 family. Furthermore, our data support the view that ERK does not participate in CDDP-induced cell death. The importance of these participations appears to be dependent on cell type. For example, while ROS and p38 MAPK were involved in the death of 293T and U937 cells, respectively, CDDP increased the ratio of pro-apoptotic/pro-survival Bcl-2 proteins in U937 cells only. Therefore, it appears that ROS, p38 MAPK and Bcl-2 family proteins may independently support CDDP-induced cell death. In contrast, JNK was found to mediate the lethality of CDDP in all cell types. The role of JNK in CDDP-induced cell death has also been proposed for other cells, e.g., cervical (17) and ovarian cancer cells (18) . Therefore, the ability of JNK to mediate CDDP-induced cell death appears to be a feature of many cell types, which suggests that the JNK pathway represents a primary target for the modulation of CDDP lethality in p53-deficient/mutated cells. Table I . Cellular components involved in CDDP-induced cell death in the absence of p53 activation. 
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293T o x x o x SNU-16 o x x x x U937 o o x x o -
Involved and non-involved components are indicated by o and x, respectively. After the indicated periods, ERK, p38 MAPK and JNK activity was analyzed by using in vitro kinase assays. The substrates used were recombinant c-Jun protein for JNK or PHAS-1 for ERK and p38 MAPK. The protein levels of these MAPKs were also probed using specific antibodies. In the case of JNK, two isoforms (p54 and p46) were detected. (B), the three cell-lines were also treated with CDDP in the presence or absence of PD 98059, SB 203580 or SP 600125, which inhibit ERK, p38 MAPK and JNK, respectively. All of these inhibitors were used at 10 μM.
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